Merck KGaA is about to spend $11.3 billion in cash on a company that sells antibodies and reagents, not a blockbuster drug or an AI platform with a slick demo. Bio-Techne is a half-century-old catalog of proteins and lab consumables that sits quietly inside almost every researcher’s freezer and a good share of diagnostics developers’ workflows. Merck agreed to pay well above the market price to get it. For a diagnostics or tools founder, the size of the check matters less than what the check is buying: a business almost nobody can rip out.
What $11.3 billion actually buys
Bio-Techne is a Minneapolis supplier with roughly 3,000 employees, more than $1.2 billion in fiscal 2025 sales, 34 locations, and 15 manufacturing sites. Its catalog runs to about 6,000 proteins and 425,000 antibodies, plus immunoassay kits, ProteinSimple analytical instruments, RNAscope spatial-biology tools, and cell-therapy materials. Merck is paying $73 a share, all cash, a 36% premium to Bio-Techne’s one-month average price, in its largest life-science acquisition since it bought Sigma-Aldrich in 2015. The deal is expected to close late this year or early next.
None of that reads like a breakthrough, and that is the point. What a strategic buyer pays a premium for here is not novelty. It is that thousands of labs and assay developers have already built and validated their work on Bio-Techne’s specific reagents. Swap a reagent and you re-run the validation. That friction is worth billions, because it means next year’s revenue arrives whether or not anyone at Bio-Techne does something clever. Merck already runs one of the world’s largest life-science supply businesses, and a deep, cataloged reagent base bolts straight onto what it sells. A buyer pays up for that kind of certainty in a way it never will for a promising pipeline.
Why the catalog is so hard to walk away from
I think about defensibility in two flavors. There is the coercive kind, where you trap a customer with contracts and pre-sold consumables, and they leave the moment a competitor offers them a door. Then there is the good kind, where you have solved the customer’s problem so completely that switching makes no sense even with the door wide open. I usually explain it with da Vinci: surgeons are trained on it, the operating room is built around it, and Intuitive keeps it easy to buy and maintain. Nobody is trapped. Leaving is simply the worse choice. Bio-Techne has quietly built the same thing in the lab. Once a diagnostics developer has validated an assay on a specific antibody, ripping it out means re-running the validation, and that is a cost almost nobody volunteers for.
That is the part worth internalizing if you are building in diagnostics or life-science tools. The unglamorous component sitting inside everyone else’s experiment does not look like much on a pitch slide, and it is easy to file under the stuff that supports the real work. But it is often the most durable thing you own, because a customer who would have to redo months of work to replace you is a customer who stays. It is worth treating that component as the business rather than the plumbing.
That is not a reason to build something dull and wait for a bank to call. Plenty of suppliers that look indispensable are one substitution away from irrelevant. The Bio-Techne kind of durability comes from being wired into work other people cannot easily redo: regulated assays, validated pipelines, materials with a documented history behind them. If you are building in diagnostics or life-science tools, ask early whether a customer could swap you out over a weekend, or whether doing so would cost them a quarter of revalidation. The second answer is the one a strategic buyer pays for.
Dave’s take
A deal like this can look like luck from the outside, a founder who happened to build something a giant wanted. It rarely is. The companies strategics pay premiums for are usually the ones built years earlier to run without any one person in the room: predictable revenue, customers held in place by their own validated workflows, a catalog that keeps selling on a slow Tuesday. An exit is not a final act you fall into. It is a design choice, and the indispensable, unglamorous version of your company is often the one worth the most.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour consultation →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →